A study from the Lupus Hopkins Cohort shows that systemic lupus erythematosus (SLE) patients with pericarditis are at risk for recurrence, and likely to be younger patients, with uncontrolled disease, and linkage to higher doses of oral prednisone.

Science and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct autoimmune diseases or viral infections, and those who had received an influenza vaccine.

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

The results of the large Phase 2b RENOIR trial showed that rosnilimab, a monoclonal antibody targeting PD-1, was effective in moderate-to-severe rheumatoid arthritis (RA) patients.

The AMA has just published the results of a U.S. Physician survey and shown MD attitudes have positively shifted regarding the use of artificial intelligence (AI) in healthcare.

Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.

A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.

BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.

The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease. 

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.